Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/wolters-kluwer-health/mutational-analysis-in-cytological-specimens-of-advanced-lung-Y2oKmegQpx
References (35)
-
H. Shigematsu, Li Lin, Takao Takahashi, M. Nomura, Makoto Suzuki, I. Wistuba, K. Fong, Hue Lee, S. Toyooka, N. Shimizu, T. Fujisawa, Ziding Feng, J. Roth, J. Herz, J. Minna, A. Gazdar (2006)
Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers.Journal of the National Cancer Institute, 97 5
-
Sae-Won Han, Tae-You Kim, P. Hwang, Soohyun Jeong, Jeong-Whun Kim, I. Choi, D. Oh, J. Kim, Dong-Wan Kim, D. Chung, S. Im, Y. Kim, J. Lee, D. Heo, Y. Bang, N. Kim (2005)
Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 11
-
A. Marchetti, C. Martella, L. Felicioni, Fabio Barassi, S. Salvatore, A. Chella, P. Camplese, T. Iarussi, F. Mucilli, A. Mezzetti, F. Cuccurullo, R. Sacco, F. Buttitta (2005)
EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 4
-
T. Takano, Y. Ohe, H. Sakamoto, K. Tsuta, Y. Matsuno, U. Tateishi, Seiichiro Yamamoto, H. Nokihara, N. Yamamoto, I. Sekine, H. Kunitoh, T. Shibata, T. Sakiyama, Teruhiko Yoshida, T. Tamura (2005)
Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 28
-
D. Eberhard, B. Johnson, L. Amler, A. Goddard, Sherry Heldens, R. Herbst, William Ince, P. Jänne, T. Januario, David Johnson, P. Klein, V. Miller, M. Ostland, D. Ramies, Dragan Sebisanovic, Jeremy Stinson, Yu Zhang, S. Seshagiri, K. Hillan (2005)
Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 25
-
Kyu-Sik Kim, Ju-yeon Jeong, Young-chul Kim, K. Na, Y. Kim, S. Ahn, S. Baek, Chang-Soo Park, C. Park, Y. Kim, S. Lim, K. Park (2005)
Predictors of the Response to Gefitinib in Refractory Non–Small Cell Lung CancerClinical Cancer Research, 11
-
H. Cortés-Funes, C. Gómez, R. Rosell, P. Valero, C. García-Girón, Ángela Velasco, A. Izquierdo, P. Diz, C. Camps, D. Castellanos, V. Alberola, F. Cardenal, J. González-Larriba, J. Viéitez, I. Maeztu, J. Sánchez, C. Queralt, C. Mayo, P. Méndez, T. Moran, M. Taron (2005)
Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients.Annals of oncology : official journal of the European Society for Medical Oncology, 16 7
-
F. Hirsch, W. Franklin, J. Mccoy, F. Cappuzzo, M. Varella-Garcia, S. Witta, P. Gumerlock, H. West, D. Gandara, P. Bunn (2006)
Predicting clinical benefit from EGFR TKIs: Not all EGFR mutations are equal.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 18_suppl
-
W. Pao, Theresa Wang, Gregory Riely, V. Miller, Qiulu Pan, M. Ladanyi, M. Zakowski, R. Heelan, M. Kris, H. Varmus (2005)
KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or ErlotinibPLoS Medicine, 2
-
E. Brambilla, W. Travis, T. Colby, B. Corrin, Y. Shimosato (2001)
The new World Health Organization classification of lung tumoursEuropean Respiratory Journal, 18
-
Y. Suzuki, M. Orita, M. Shiraishi, K. Hayashi, T. Sekiya (1990)
Detection of ras gene mutations in human lung cancers by single-strand conformation polymorphism analysis of polymerase chain reaction products.Oncogene, 5 7
-
H. Shigematsu, A. Gazdar (2006)
Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancersInternational Journal of Cancer, 118
-
X. Mu, Long-yun Li, Xiao Zhang, Men-Zhao Wang, R. Feng, Q. Cui, Hai-sheng Zhou, B. Guo (2005)
Gefitinib-Sensitive Mutations of the Epidermal Growth Factor Receptor Tyrosine Kinase Domain in Chinese Patients with Non–Small Cell Lung CancerClinical Cancer Research, 11
-
T. Mitsudomi, T. Kosaka, H. Endoh, Y. Horio, T. Hida, S. Mori, S. Hatooka, M. Shinoda, Takashi Takahashi, Y. Yatabe (2005)
Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 11
-
T. Kosaka, Y. Yatabe, H. Endoh, H. Kuwano, Takashi Takahashi, T. Mitsudomi (2004)
Mutations of the Epidermal Growth Factor Receptor Gene in Lung CancerCancer Research, 64
-
N. Fujimoto, M. Wislez, Jie Zhang, K. Iwanaga, J. Dackor, Amy Hanna, Shailaja Kalyankrishna, D. Cody, R. Price, Mitsuo Sato, J. Shay, J. Minna, M. Peyton, Ximing Tang, E. Massarelli, R. Herbst, D. Threadgill, I. Wistuba, J. Kurie (2005)
High expression of ErbB family members and their ligands in lung adenocarcinomas that are sensitive to inhibition of epidermal growth factor receptor.Cancer research, 65 24
-
徳毛 誠樹 (2005)
The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers -
J. Paez, P. Jänne, Jeffrey Lee, Sean Tracy, H. Greulich, S. Gabriel, P. Herman, F. Kaye, N. Lindeman, T. Boggon, K. Naoki, H. Sasaki, Y. Fujii, M. Eck, W. Sellers, B. Johnson, M. Meyerson (2004)
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 304
-
S. Mashiyama, T. Kayama, R. Katakura, T. Yoshimoto, Y. Murakami, T. Sekiya, K. Hayashi (1991)
Detection of p53 gene mutations in human brain tumors by single-strand conformation polymorphism analysis of polymerase chain reaction products.Oncogene, 6 8
-
C. Mountain (1997)
Revisions in the International System for Staging Lung Cancer.Chest, 111 6
-
Duykhanh Pham, M. Kris, Gregory Riely, I. Sarkaria, T. McDonough, S. Chuai, E. Venkatraman, V. Miller, M. Ladanyi, W. Pao, R. Wilson, Bhuvanesh Singh, V. Rusch (2006)
Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 11
-
L. Paz-Ares, J. Sánchez, A. García-Velasco, B. Massutí, G. López-Vivanco, Mariano Provencio, A. Montes, Dolores Isla, M. Amador, R. Rosell (2006)
A prospective phase II trial of erlotinib in advanced non-small cell lung cancer (NSCLC) patients (p) with mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR).Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 18_suppl
-
Gregory Riely, W. Pao, Duykhanh Pham, Allan Li, N. Rizvi, E. Venkatraman, M. Zakowski, M. Kris, M. Ladanyi, V. Miller (2006)
Clinical Course of Patients with Non–Small Cell Lung Cancer and Epidermal Growth Factor Receptor Exon 19 and Exon 21 Mutations Treated with Gefitinib or ErlotinibClinical Cancer Research, 12
-
M. Tarón, Y. Ichinose, R. Rosell, T. Mok, B. Massutí, L. Zamora, J. Maté, C. Manegold, M. Ono, C. Queralt, T. Jahan, J. Sánchez, M. Sánchez-Ronco, V. Hsue, D. Jablons, J. Sánchez, T. Morán (2005)
Activating Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor Are Associated with Improved Survival in Gefitinib-Treated Chemorefractory Lung AdenocarcinomasClinical Cancer Research, 11
-
V. Villaflor, L. Buckingham, M. Gale, J. Coon, A. Mauer, T. Muzzafar, K. Kaiser, T. Zusag, L. Faber, P. Bonomi (2005)
EGFR mutations and pAKT expression as potential predictors of gefitinib efficacy in non-small cell lung cancer (NSCLC) patients (pts)Journal of Clinical Oncology, 23
-
Susumu Kobayashi, T. Boggon, Tajhal Dayaram, P. Jänne, O. Kocher, M. Meyerson, B. Johnson, M. Eck, D. Tenen, B. Halmos (2005)
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.The New England journal of medicine, 352 8
-
T. Lynch, D. Bell, Raffaella Sordella, S. Gurubhagavatula, R. Okimoto, Brian Brannigan, Patricia Harris, Sara Haserlat, J. Supko, F. Haluska, D. Louis, D. Christiani, J. Settleman, D. Haber (2004)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.The New England journal of medicine, 350 21
-
H. Greulich, Tzu-Hsiu Chen, W. Feng, P. Jänne, James Alvarez, M. Zappaterra, Sara Bulmer, D. Frank, W. Hahn, W. Sellers, M. Meyerson (2005)
Oncogenic Transformation by Inhibitor-Sensitive and -Resistant EGFR MutantsPLoS Medicine, 2
-
Xiaotong Zhang, L-Y Li, X. Mu, Q. Cui, X.-Y. Chang, W. Song, S-L Wang, Mengzhao Wang, W. Zhong, Lanjun Zhang (2005)
The EGFR mutation and its correlation with response of gefitinib in previously treated Chinese patients with advanced non-small-cell lung cancer.Annals of oncology : official journal of the European Society for Medical Oncology, 16 8
-
T. Chou, C. Chiu, Ling-Hui Li, C. Hsiao, C. Tzen, Kuo‐Ting Chang, Yuh-Min Chen, R. Perng, S. Tsai, C. Tsai (2005)
Mutation in the Tyrosine Kinase Domain of Epidermal Growth Factor Receptor Is a Predictive and Prognostic Factor for Gefitinib Treatment in Patients with Non–Small Cell Lung CancerClinical Cancer Research, 11
-
W. Pao, V. Miller, M. Zakowski, J. Doherty, K. Politi, I. Sarkaria, Bhuvanesh Singh, R. Heelan, V. Rusch, L. Fulton, E. Mardis, Doris Kupfer, R. Wilson, M. Kris, H. Varmus (2004)
EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.Proceedings of the National Academy of Sciences of the United States of America, 101 36
-
D. Jackman, B. Yeap, L. Sequist, N. Lindeman, A. Holmes, V. Joshi, D. Bell, M. Huberman, B. Halmos, M. Rabin, D. Haber, T. Lynch, M. Meyerson, B. Johnson, P. Jänne (2006)
Exon 19 Deletion Mutations of Epidermal Growth Factor Receptor Are Associated with Prolonged Survival in Non–Small Cell Lung Cancer Patients Treated with Gefitinib or ErlotinibClinical Cancer Research, 12
-
L. Paz-Ares, J. Douillard, P. Koralewski, C. Manegold, E. Smit, J. Reyes, G. Chang, W. John, P. Peterson, C. Obasaju, M. Lahn, D. Gandara (2006)
Phase III study of gemcitabine and cisplatin with or without aprinocarsen, a protein kinase C-alpha antisense oligonucleotide, in patients with advanced-stage non-small-cell lung cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 9
-
S. Ahrendt, P. Decker, Enas Alawi, Yong‐ran Zhu, M. Sanchez-Cespedes, Stephen Yang, G. Haasler, A. Kajdacsy‐Balla, M. Demeure, D. Sidransky (2001)
Cigarette smoking is strongly associated with mutation of the K‐ras gene in patients with primary adenocarcinoma of the lungCancer, 92
-
S. Rodenhuis, R. Slebos, Angelina Boot, Siegina Evers, W. Mooi, S. Wagenaar, P. Bodegom, J. Bos, Al Leiden (1988)
Incidence and possible clinical significance of K-ras oncogene activation in adenocarcinoma of the human lung.Cancer research, 48 20
- ISSN
- 1556-0864
- DOI
- 10.1097/JTO.0b013e31815ba1fa
- pmid
- 18090579
- Publisher site
- See Article on Publisher Site
Abstract
ORIGINAL ARTICLE Mutational Analysis in Cytological Specimens of Advanced Lung Adenocarcinoma: A Sensitive Method for Molecular Diagnosis Laura Boldrini, PhD,* Silvia Gisfredi, PhD,* Silvia Ursino, PhD,* Tiziano Camacci,* Editta Baldini, MD,† Franca Melfi, MD,‡ and Gabriella Fontanini, MD* he discovery that somatic mutations in the epidermal Introduction: The discovery that somatic mutations in the epider- Tgrowth factor receptor (EGFR) gene in lung adenocarci- mal growth factor receptor (EGFR) gene are associated with sensi- nomas are associated with sensitivity to the EGFR tyrosine tivity to the EGFR tyrosine kinase inhibitors (TKIs) in lung adeno- 1,2 3 kinase inhibitors (TKI) gefitinib and erlotinib, whereas carcinomas, whereas Kras mutations are associated with resistance, 4–6 Kras mutations are associated with resistance to TKIs, has has generated excitement among both clinicians and researchers generated excitement among clinicians and researchers study- studying non-small cell lung cancer (NSCLC). Mutational analysis ing non-small cell lung cancer (NSCLC). Mutational analysis may soon be very useful in choosing among a wide range of targeted should soon be very useful to clinicians in choosing among therapies to individualize treatment to tumor characteristics. This the wide range of targeted therapies that can be implemented analysis would be even more useful in
Journal
Journal of Thoracic Oncology – Wolters Kluwer Health
Published: Dec 1, 2007